BR112015014391B1 - compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos - Google Patents

compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos Download PDF

Info

Publication number
BR112015014391B1
BR112015014391B1 BR112015014391-1A BR112015014391A BR112015014391B1 BR 112015014391 B1 BR112015014391 B1 BR 112015014391B1 BR 112015014391 A BR112015014391 A BR 112015014391A BR 112015014391 B1 BR112015014391 B1 BR 112015014391B1
Authority
BR
Brazil
Prior art keywords
lys
boc
str
group
compound
Prior art date
Application number
BR112015014391-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015014391A2 (pt
Inventor
Jayanta Haldar
Chandradhish Ghosh
Goutham Belagula Manjunath
Padma Akkapeddi
Original Assignee
The Secretary Of State For Health
Jawaharlal Nehru Centre For Advanced Scientific Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Secretary Of State For Health, Jawaharlal Nehru Centre For Advanced Scientific Research filed Critical The Secretary Of State For Health
Publication of BR112015014391A2 publication Critical patent/BR112015014391A2/pt
Publication of BR112015014391B1 publication Critical patent/BR112015014391B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015014391-1A 2012-12-18 2013-12-18 compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos BR112015014391B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN5299CH2012 2012-12-18
IN5299/CHE/2012 2012-12-18
PCT/IB2013/061090 WO2014097178A1 (en) 2012-12-18 2013-12-18 Antimicrobial compounds, their synthesis and applications thereof

Publications (2)

Publication Number Publication Date
BR112015014391A2 BR112015014391A2 (pt) 2017-07-11
BR112015014391B1 true BR112015014391B1 (pt) 2020-11-03

Family

ID=54148251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014391-1A BR112015014391B1 (pt) 2012-12-18 2013-12-18 compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos

Country Status (9)

Country Link
US (1) US9783490B2 (cg-RX-API-DMAC7.html)
EP (1) EP2934563B1 (cg-RX-API-DMAC7.html)
JP (1) JP6533466B2 (cg-RX-API-DMAC7.html)
CN (1) CN104981249B (cg-RX-API-DMAC7.html)
AU (1) AU2013365769B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015014391B1 (cg-RX-API-DMAC7.html)
CA (1) CA2894202A1 (cg-RX-API-DMAC7.html)
HK (1) HK1210437A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014097178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566149B (zh) * 2016-03-02 2017-05-24 郑州大学 具有抗菌活性的查尔酮阳离子抗菌肽模拟物及其制备方法
CN106995384B (zh) * 2017-04-21 2018-12-11 郑州大学 具有抗菌活性的二烷基阳离子两亲性抗菌肽模拟物及其制备方法
CN120118207A (zh) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07501085A (ja) 1992-09-03 1995-02-02 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
JPH09507846A (ja) * 1993-12-30 1997-08-12 スミスクライン・ビーチャム・コーポレイション フェニルメチルヘキサンアミドおよびその使用
US5663148A (en) 1994-07-12 1997-09-02 Abbott Laboratories Anaphylatoxin receptor ligands containing lipophilic residues
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
AU697565B2 (en) 1995-12-12 1998-10-08 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivative or salt thereof and medicine comprising the same
CA2217550A1 (en) * 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
RU2200154C2 (ru) * 1997-12-12 2003-03-10 Дайичи Файн Кемикал Ко., Лтд. Новые ингибиторы металлопротеиназ
AU2180201A (en) * 1999-11-30 2001-06-12 Aventis Pharma S.A. Hydroxamic acid macrocyclic derivatives, preparation method and compositions containing same
JP2002161084A (ja) * 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
US20080118525A1 (en) * 2006-10-04 2008-05-22 Oreola Donini Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
US8097582B2 (en) * 2006-05-09 2012-01-17 Neobiotics Ab Peptide derivatives useful as antimicrobial agents and for treating wounds
JP2010512417A (ja) * 2006-12-11 2010-04-22 ワイス エルエルシー イオンチャネルモジュレータ−
CN102757477B (zh) * 2011-04-27 2014-09-03 首都医科大学 烯丙基半胱氨酰氨基酸甲酯衍生物及其合成方法和应用
DK2709619T3 (en) * 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS

Also Published As

Publication number Publication date
CA2894202A1 (en) 2014-06-26
JP2016504330A (ja) 2016-02-12
WO2014097178A1 (en) 2014-06-26
BR112015014391A2 (pt) 2017-07-11
EP2934563A4 (en) 2016-08-17
US20150329478A1 (en) 2015-11-19
HK1210437A1 (en) 2016-04-22
US9783490B2 (en) 2017-10-10
CN104981249B (zh) 2018-06-19
EP2934563A1 (en) 2015-10-28
EP2934563B1 (en) 2020-07-08
AU2013365769B2 (en) 2018-03-15
JP6533466B2 (ja) 2019-06-19
CN104981249A (zh) 2015-10-14
AU2013365769A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
Konai et al. Membrane active phenylalanine conjugated lipophilic norspermidine derivatives with selective antibacterial activity
Ghosh et al. Small molecular antibacterial peptoid mimics: the simpler the better!
Wang et al. pH-responsive antimicrobial peptide with selective killing activity for bacterial abscess therapy
AU2001268512A1 (en) Chemically-modified peptides, compositions, and methods of production and use
DE102007036128A1 (de) Antibiotische Peptide
Yang et al. Antibacterial and antibiofilm formation activities of pyridinium-based cationic pillar [5] arene against Pseudomonas aeruginosa
BR112016030580B1 (pt) Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas
CN103435686A (zh) 抗耐药性细菌感染多肽Cbf-14及其用途
US11059860B2 (en) Biocidal peptide and preparation based thereon
BR112021009746A2 (pt) Composição para injeção e método de preparo da mesma
US20110152175A1 (en) Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof
CN104292301A (zh) 一种小分子合成抗菌肽及其制备方法与应用
CN118638188B (zh) 数据库辅助设计靶向大肠杆菌抗菌肽及其制备方法和应用
CN120865346A (zh) 小分子抗菌多肽、制备方法及其应用
JP6533466B2 (ja) 抗菌性化合物、その合成およびその適用
CN102391362B (zh) 一组动物源性阳离子抗菌肽及其应用
CN102827288B (zh) 一种酸激活csp靶向抗菌肽及其制备和应用
US20170218024A1 (en) Low substituted polymyxins and compositions thereof
CN114989246B (zh) Fk3多肽类似物及其应用
CN117138024B (zh) 一种万古霉素-抗菌肽偶合物及其应用
EP4419208A1 (de) 4-aminophenylphosphorylcholin-verbindungen zur blockade von c-reaktivem protein
CN104356202A (zh) 一种阳离子抗菌肽及其制备方法与应用
CN121574193A (zh) 基于fk3的碳硼烷偶联肽及其制备方法和应用
Sheyi et al. Self‐Assembly of Branching and Linear Synthetic Polycationic Peptides in Phosphate Buffer and Its Impact on Antimicrobial Activity
Ghosh Development of L-Lysine-based small molecules as broad-spectrum antimicrobial agents

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 8A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2649 DE 13-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.